You are Here : Moneycontrol Forum Forum Topics Stocks

Samrat Pharma

Samrat Pharma
BSE 252.85 -1.27%
NSE NT*

Sector : Pharmaceuticals

Samrat Pharma
Add to
Opinions 2318
4034
Followers

Can I buy Samrat Pharma, Should I buy Samrat Pharma, Do I buy Samrat Pharma?

  • BSE

    252.85 -1.27%

  • NSE

    NT*

5 Day

Jul 28

BSE

266.75 -3.93 %

Volume 9930

Jul 29

BSE

259.45 -2.74 %

Volume 4344

Jul 30

BSE

260.90 0.56 %

Volume 1602

Aug 02

BSE

258.55 -0.9 %

Volume 4268

Aug 03

BSE

265.90 2.84 %

Volume 21003

Your Strategy BUYSELLHOLD

Aug 05, 14:10

We take the quality of the messages posted on forum as seriously as our articles. Kindly follow our Code of Conduct and refrain from posting any abusive, promotional or gibberish content on forum.
Disclaimer : The views expressed in the forum are the views of the user writing the post, and not that of moneycontrol.com. You agree, by accessing this forum, that moneycontrol.com bears no liability for any posts on this forum or, any losses suffered by following any advice posted on this forum. moneycontrol.com operates this real time, open, unmoderated, private forum for users to exchange information and to discuss various investing techniques. moneycontrol.com or, its personnel do not post anything, or vet the content posted, on this forum. moneycontrol.com reserves the right to deny service to anyone. You, and not moneycontrol.com, assume the entire cost and risk of any trading you choose to undertake. You are solely responsible for making your own investment decisions. If you choose to engage in such transactions with or without seeking advice from a licensed and qualified financial advisor or entity, then such decision and any consequences flowing therefrom are your sole responsibility.
Buy
What makes you think Havells India is a Buy?

Price

  • BSE

    252.85 -1.27%

  • NSE

    NT*

Share Target

Ok

Get your own permanent - nickname

Choose your nickname

Your permanent Nickname can be distinct from your username and no one need know the link between the two.

Sections